Immunotherapies for cancer and infectious diseases
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing immune-targeted therapies for the treatment of cancers and infectious diseases.
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing immune-targeted therapies for the treatment of cancers and infectious diseases.
Latest News
- April 18, 2018 - Transgene Presents Data on a Novel Viral Vector with Remarkable Anticancer Activity at AACR 2018
- March 21, 2018 - Transgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses
- March 15, 2018 - Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018
- January 17, 2018 - First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology)
